Trial Profile
Intravitreal Aflibercept treatment in RAP-Lesions, PED, hemorrhagic CNV and PCV
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Sep 2021
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Choroidal neovascularisation; Ocular haemorrhage; Polypoidal choroidal vasculopathy; Retinal detachment; Retinal neovascularisation; Wet age-related macular degeneration
- Focus Therapeutic Use
- 26 Jul 2018 Status changed from recruiting to completed.
- 12 Nov 2014 New trial record